Abstract:Due to the poor permeability across Gram-negative bacterial membranes and the troublesome bacterial efflux mechanism, only a few GyrB/ParE inhibitors with potent activity against Gram-negative pathogens have been reported. Among them, pyrimido[4,5-b]indole derivatives represented by GP-1 demonstrated excellent broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria but were limited by hERG inhibition and poor pharmacokinetics profile. To improve their drug-like properties, we designed a series of novel pyrimido[4,5-b]indole derivatives based on the tricyclic scaffold of GP-1 and the C-7 moiety of acorafloxacin. These efforts have culminated in the discovery of a promising compound 18r with reduced hERG liability and an improved PK profile. Compound 18r exhibited superior broad-spectrum in vitro antibacterial activity compared to GP-1, including a variety of clinical multidrug G– pathogens, especially Acinetobacter baumannii, and the in vivo efficacy was also demonstrated in a neutropenic mouse thigh model of infection with multidrug-resistant A. baumannii.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00621?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00621</a>.More MIC data and details of tested compounds for <a class="ref showTableEvent internalNav" href="#tbl1">Tables </a><a class="ref showTableEvent internalNav" href="#tbl1">1</a>, <a class="ref showTableEvent internalNav" href="#tbl3">3</a>, and <a class="ref showTableEvent internalNav" href="#tbl4">4</a>; more MIC data and details of tested compounds for <a class="ref showTableEvent internalNav" href="#tbl5">Table </a><a class="ref showTableEvent internalNav" href="#tbl5">5</a>; metabolite identification of compound 18k in rat liver microsomes; proposed metabolic pathways of compound 18k; preparation and characterization data of all intermediates; NMR spectra and HRMS data of final compounds; and HPLC traces for lead compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00621/suppl_file/jm1c00621_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00621/suppl_file/jm1c00621_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens

Novel Naphthalimide Nitroimidazoles As Multitargeting Antibacterial Agents Against Resistant Acinetobacter Baumannii.

A Comparative Insight on the Newly Emerging Rifamycins: Rifametane, Rifalazil, TNP-2092 and TNP-2198

Redesign of Rifamycin Antibiotics to Overcome ADP‐Ribosylation‐Mediated Resistance

Dual Mechanism of Action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis

Design, synthesis and biological evaluation of 3-substituted-2-thioxothiazolidin-4-one (rhodanine) derivatives as antitubercular agents against Mycobacterium tuberculosis protein tyrosine phosphatase B

Intracellular Activity of Poly (DL-Lactide-co-Glycolide) Nanoparticles Encapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid, or Ethambutol on Multidrug-Resistant Mycobacterium tuberculosis

Phenotypic‐based Discovery and Exploration of a Resorufin Scaffold with Activity against Mycobacterium Tuberculosis

Rational exploration of 2,4-diaminopyrimidines as DHFR inhibitors active against Mycobacterium abscessus and Mycobacterium avium, two emerging human pathogens

GaMF1.39's antibiotic efficacy and its enhanced antitubercular activity in combination with clofazimine, Telacebec, ND-011992, or TBAJ-876

Synthesis, Activity, Toxicity, and In Silico Studies of New Antimycobacterial N-Alkyl Nitrobenzamides

Lower Cytotoxicity, High Stability, and Long-Term Antibacterial Activity of a Poly(methacrylic Acid)/isoniazid/rifampin Nanogel Against Multidrug-Resistant Intestinal Mycobacterium Tuberculosis.

A novel synergistic enzyme-antibiotic therapy with immobilization of mycobacteriophage Lysin B enzyme onto Rif@UiO-66 nanocomposite for enhanced inhaled anti-TB therapy; Nanoenzybiotics approach

Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents

Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis

Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5- b ]indole Derivatives Against Gram-Negative Multidrug-Resistant Pathogens

In Vitro and in Vivo Activities of a New Lead Compound I2906 Against Mycobacterium Tuberculosis

A Dual‐Responsive Antibiotic‐Loaded Nanoparticle Specifically Binds Pathogens and Overcomes Antimicrobial‐Resistant Infections

Fragment-based discovery of a new class of inhibitors targeting mycobacterial tRNA modification

Design, synthesis, and bioactivity investigation of novel cyclic lipopeptide antibiotics targeting top-priority multidrug-resistant gram-negative bacteria

Synthesis and Antimicrobial Evaluation of Amixicile-Based Inhibitors of the Pyruvate-Ferredoxin Oxidoreductases of Anaerobic Bacteria and Epsilonproteobacteria